Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 12Unknown 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Neoplasm Metastasis 2Lymphoma, Follicular 2Carcinoma, Renal Cell 2Recurrence 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Interferon-alpha × Clear all
NCT00005987 2017-11-29

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
87 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡